Indaptus Therapeutics expands patent portfolio in China, Japan, Israel

Indaptus Therapeutics (INDP) has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus and human immunodeficiency virus, two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments.